Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer
about
Oncolytic viruses as therapeutic cancer vaccinesOncolytic viruses: finally deliveringp21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.Anti-tumor function of double-promoter regulated adenovirus carrying SEA gene, in the treatment of bladder cancer.The E1B19K oncoprotein complexes with Beclin 1 to regulate autophagy in adenovirus-infected cellsLow-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer.Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.Adenoviruses induce autophagy to promote virus replication and oncolysis.Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo.Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators.RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian CancerDownregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirusCombination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo.Down-regulation of multiple cell survival proteins in head and neck cancer cells by an apoptogenic mutant of adenovirus type 5.Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time.A p53-independent apoptotic mechanism of adenoviral mutant E1A was involved in its selective antitumor activity for human cancer.Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets.Oncolytic viruses & their specific targeting to tumour cells.Targeting autophagy to enhance oncolytic virus-based cancer therapy.Adenovirus E1B 19-kilodalton protein modulates innate immunity through apoptotic mimicry.In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells.Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers.Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression.Development of an Oncolytic Adenovirus with Enhanced Spread Ability through Repeated UV Irradiation and Cancer SelectionThe E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro.RIPK3 promotes adenovirus type 5 activity.Human dendritic cells efficiently phagocytose adenoviral oncolysate but require additional stimulation to mature.Genetically engineered oncolytic adenovirus induces autophagic cell death through an E2F1-microRNA-7-epidermal growth factor receptor axis.Targeting Autophagy for Oncolytic Immunotherapy.
P2860
Q21245758-51F6A49D-A183-4332-B501-1909BCD21FB2Q26772039-F9E9417C-5781-4C54-9C76-D79EFEA499DDQ33997928-E35C83A6-5784-4E09-8777-56F39D34C221Q34048741-47DED1D0-CAD9-4A05-91DA-7D373F1B5F21Q34126467-DAEEFCAA-DF6D-459F-B5E8-5E8993E8BD19Q34430268-0BD77B54-0097-4E60-AA4B-1146D92C4287Q34621683-A323C1F7-9FFC-4DD8-8E69-EB0DEA7D1120Q34755147-144F87DC-B442-4F5E-A7DB-D0947CF1C3BAQ35040642-56F7185C-ABC4-4322-9D29-F66610DF9B1AQ36220647-1456A6E6-E898-445D-826A-0D5C84ADB6C2Q36323413-14360FD6-6743-4216-A545-98DC8186F2BCQ36472419-015DE7D4-6AF9-47E6-B822-5E681BB20F9BQ36642630-3B9AA9B2-2A9A-4D9E-AD0E-39940F0E7EFAQ37147851-1582603C-6787-4444-AAC0-EA87ED66E68FQ37414129-39931942-9717-40E5-AECE-1CBF53434DEDQ37448942-5E707192-8812-4471-B886-565E13202466Q37565456-97CAE49D-EFC1-4EC9-BAF6-27BBEA7794B4Q37707676-6C978F65-09D6-4D6D-9554-C3CA9110E046Q38033591-20DCB7D3-77DD-484F-AC28-78C7709A0C28Q38061306-F26F4E5A-C16B-4CCE-A457-10CE4D2B883DQ38089106-6A036B3C-BC8B-4AC3-AFEB-B7E42C4DA700Q38330182-2825A28C-69A3-40BA-823D-4F1D77CE5667Q38850871-F91DAC98-D2C8-4548-B829-2B54E7CE255EQ39752863-860B317C-29B7-41E9-A3EB-F3443300A8FEQ39882822-B69F0834-843A-49D0-B2B6-4ECECA932A39Q40090311-1F59018F-873D-4EC2-B68C-323E7F846318Q40695592-6806577B-2A23-44C9-BB38-D40DBDB69530Q40913003-DF9A6C14-DC3B-441A-99B8-FB0F52FC6E47Q42202353-0BAC247D-FDE0-409D-82A8-8875DD01DF7AQ47296094-87015C49-389B-4A49-8A63-4D0FA41CD3A6Q53809292-9FAC333C-E7BA-4F33-9690-7BD5C4F9C2B0Q54315299-F358AAA0-4A2F-468B-B086-82C22F4D3129Q55171421-54A5FEAA-C916-43F9-9953-AA7AF96A3EB1
P2860
Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Oncolytic adenoviral mutants i ...... d cell death in ovarian cancer
@ast
Oncolytic adenoviral mutants i ...... d cell death in ovarian cancer
@en
type
label
Oncolytic adenoviral mutants i ...... d cell death in ovarian cancer
@ast
Oncolytic adenoviral mutants i ...... d cell death in ovarian cancer
@en
prefLabel
Oncolytic adenoviral mutants i ...... d cell death in ovarian cancer
@ast
Oncolytic adenoviral mutants i ...... d cell death in ovarian cancer
@en
P2093
P2860
P921
P356
P1433
P1476
Oncolytic adenoviral mutants i ...... d cell death in ovarian cancer
@en
P2093
A Eddaoudi
I A McNeish
N R Lemoine
P2860
P2888
P304
P356
10.1038/SJ.ONC.1210977
P407
P577
2007-12-10T00:00:00Z
P5875
P6179
1027606037